What is BMEA's P/E ratio?

Biomea Fusion Inc (BMEA) currently trades at a P/E ratio of 18.81.

Biomea Fusion Inc reports a Return on Equity (ROE) of -240.13%.

What is BMEA's dividend yield?

Biomea Fusion Inc offers a dividend yield of 0.00%.

What is BMEA's Quality Score?

Our AI rates BMEA's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy BMEA?

Our AI Timing Score for BMEA is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does BMEA belong to?

Biomea Fusion Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Biomea Fusion Inc (BMEA) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

BMEA AI Analysis Summary

Our AI summary for BMEA: Biomea Fusion Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 18.81, ROE of -240.13%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

BMEA

Biomea Fusion Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 99

USD 1.23

0.03 (2.50%) Day Change

Watchlist Portfolio Compare Chart

18.81

P/E

0.07

D/E

-240.1%

ROE

-96.9%

ROA

0.00%

Div Yield

-1.77

PEG

BIOMEA FUSION INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 1.23 Price 0.03 (2.50%) Day Change	NEWS SCORE: 99

BMEA, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...

Loading chart...

54 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	99
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.23
PBV / Sector	4.63 / 44,022.72
Earning Per Share	-0.64

PE / Sector	18.81 / 19.17
PEG or PE/Growth / Sector	-1.77 / 1.24
Average 1M Daily Value	0.83 M GREAT
Average 1W Daily Value	0.63 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.24
NPM Average (%) / Sector	N/A / -1,697.63
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-96.91 / 185,260.96
ROA Average (%) / Sector	-99.22 / 36,684.70
ROA Change Average (%) / Sector	35.70 / 422,221.66 GREAT
ROE (%) / Sector	-240.13 / 243,762.23
ROE Average (%) / Sector	-172.13 / 48,758.47
ROE Change Average (%) / Sector	68.53 / 424,968.10 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 07:59:54
Symbol	BMEA
Name	BIOMEA FUSION INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	72.30 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	86.76 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 1599 Industrial Road, San Carlos, CA, United States, 94070

Phone: 650 980 9099

Website: https://biomeafusion.com

Sector: Healthcare >> Biotechnology

Description: Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.